<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430050</url>
  </required_header>
  <id_info>
    <org_study_id>65954</org_study_id>
    <secondary_id>5K24DA038240-03</secondary_id>
    <nct_id>NCT03430050</nct_id>
  </id_info>
  <brief_title>Progesterone for Cannabis Withdrawal</brief_title>
  <official_title>Progesterone for the Treatment of Cannabis Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sex and gender differences in behavioral, biological, and clinical correlates of substance
      use disorders are myriad, yet there exists a dearth of gender-informed treatment options.
      Ovarian hormones have been identified as potential mechanisms of these disparities , and
      recent clinical trials have begun to examine their utility as possible pharmacotherapeutic
      agents. The ovarian hormone progesterone has shown promise as a treatment for female cocaine
      and nicotine users, but has not yet been tested for cannabis. Gender differences in cannabis
      withdrawal, which is associated with relapse, are pronounced and several studies report more
      severe and impairing withdrawal symptoms in women compared to men. Developing pharmacological
      interventions for cannabis withdrawal remains an important priority given the significant
      cognitive, psychiatric, and physical consequences of heavy cannabis use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Substantial evidence demonstrates sex and gender differences in the behavioral, biological,
      and clinical correlates of substance use disorders. Men tend to initiate use earlier and have
      higher lifetime prevalence rates of disorder, but women demonstrate more severe withdrawal,
      more rapid progression from first use to disorder, and greater likelihood of comorbid
      psychiatric disorder. A growing literature suggests that the ovarian hormones progesterone
      and estradiol may play a key role in these differences. Evidence from preclinical and
      clinical research suggests that estradiol enhances drug sensitivity and related behavior,
      while progesterone attenuates drug sensitivity and behavior. As such, recent clinical trials
      investigating exogenous progesterone as a potential pharmacologic intervention have shown
      attenuated subjective and physiological effects of cocaine and nicotine in drug-dependent
      women, and improved cognitive performance in female smokers. While progesterone has shown
      promise as a treatment for women with cocaine and nicotine use disorder, it has not yet been
      tested for cannabis.

      To date, there are no approved pharmacologic interventions for cannabis use disorder (CUD)
      despite numerous clinical trials. Cannabis withdrawal is one potential target for CUD
      medication development research as withdrawal increases risk of relapse. Important gender
      differences in cannabis withdrawal have been identified warranting gender-based
      investigation. Several studies have found that women experience more severe and impairing
      withdrawal symptoms, primarily physiological (e.g. stomach aches, headaches, nausea) and
      mood-related (e.g. irritability, mood swings), compared to men. As a naturally occurring sex
      hormone, progesterone may effectively address these gender differences. The proposed pilot
      study investigates the feasibility and efficacy of exogenous progesterone administration for
      cannabis withdrawal among female cannabis users.

      Specific Aim 1: Test the feasibility of exogenous progesterone administration among cannabis
      users.

      Hypothesis 1: Exogenous progesterone administration will induce normative elevations in
      progesterone comparable to the luteal phase of female menstrual cycle and will be
      well-tolerated by participants.

      Specific Aim 2: Examine the efficacy of exogenous progesterone on cannabis withdrawal.

      Hypothesis 2: Compared to placebo, progesterone will attenuate withdrawal symptoms among
      heavy-cannabis-using women.

      Exploratory Aim: Examine the effect of exogenous progesterone on cognitive functioning during
      cannabis withdrawal.

      Exploratory hypothesis: Compared to placebo, progesterone will enhance cognitive functioning
      among heavy-cannabis-using women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Actual">April 4, 2018</completion_date>
  <primary_completion_date type="Actual">April 4, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Salivary Progesterone Level</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Participants took progesterone or placebo for 5 days. Salivary progesterone was measured each day. Change score was calculating by subtracting Day 1 progesterone levels from Day 5 progesterone levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cannabis Withdrawal Scale Score.</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Participants took progesterone or placebo for 5 days. The Cannabis Withdrawal Scale was administered each day. The 19-item scale is used to measure cannabis withdrawal symptoms and negative impact on daily life. The item scores range from 0 - not at all to 10- Extremely. Scores on all items are summed to attain the scale score, so individuals can score between 0-190. Higher scores indicates more severe withdrawal symptoms and greater negative impact. Change score was calculating by subtracting Day 1 CWS scores from Day 5 CWS scores. A positive change score reflects an increase in withdrawal symptoms, while a negative change score reflects a decrease in withdrawal symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <condition>Cannabis Withdrawal</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone capsule</description>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule. Manufactured to mimic progesterone 200mg capsule.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide informed consent and function at an intellectual level sufficient to
             allow accurate completion of all assessment instruments and study procedures.

          2. Age 18-45, with regular menses (every 25-35 days).

          3. Report using cannabis at least 5 days per week, for at least the past year.

          4. Consent to remain abstinent from alcohol for 12 hours prior to study visits, and all
             other drugs other than cannabis or nicotine for the duration of the study.

          5. Consent to random assignment.

        Exclusion Criteria:

          1. Participants who are pregnant, nursing, amennorheic, or using oral contraceptives.

          2. History of major medical illnesses; including liver diseases, abnormal vaginal
             bleeding, suspected or known malignancy, thrombophlebitis, deep vein thrombosis,
             pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of
             stroke or other medical conditions that the investigator deems as contraindicated for
             the patient to be in the study;

          3. Regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics) and recent/current psychiatric diagnosis and treatment for Axis I
             disorders including major depression, bipolar affective disorder, schizophrenia or
             panic disorder.

          4. Current suicidal or homicidal risk. Any subject who endorses suicidal ideation will be
             seen by a licensed clinician in the Addiction Sciences Division who will determine the
             best course of action to ensure patient safety.

          5. Known allergy to progesterone or peanuts (vehicle for micronized progesterone).

          6. Unwilling or unable to maintain abstinence from alcohol 12 hours prior to study
             visits, and all other drugs other than cannabis or nicotine for the duration of the
             study.

          7. Meet DSM-5 criteria for moderate to severe substance use disorder (other than
             nicotine, cannabis, or alcohol) within the past year.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Normally cycling menstruating females.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J Sherman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <results_first_submitted>February 13, 2019</results_first_submitted>
  <results_first_submitted_qc>April 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2019</results_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progesterone</keyword>
  <keyword>Ovarian hormones</keyword>
  <keyword>Gender</keyword>
  <keyword>Cannabis</keyword>
  <keyword>Withdrawal</keyword>
  <keyword>Cognitive functioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03430050/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Progesterone</title>
          <description>Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Progesterone: Progesterone capsule</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Placebo: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Progesterone</title>
          <description>Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Progesterone: Progesterone capsule</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Placebo: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Salivary Progesterone Level</title>
        <description>Participants took progesterone or placebo for 5 days. Salivary progesterone was measured each day. Change score was calculating by subtracting Day 1 progesterone levels from Day 5 progesterone levels.</description>
        <time_frame>Day 1 and Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Progesterone: Progesterone capsule</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Placebo: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Salivary Progesterone Level</title>
          <description>Participants took progesterone or placebo for 5 days. Salivary progesterone was measured each day. Change score was calculating by subtracting Day 1 progesterone levels from Day 5 progesterone levels.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.86" spread="24.21"/>
                    <measurement group_id="O2" value="97.87" spread="14.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cannabis Withdrawal Scale Score.</title>
        <description>Participants took progesterone or placebo for 5 days. The Cannabis Withdrawal Scale was administered each day. The 19-item scale is used to measure cannabis withdrawal symptoms and negative impact on daily life. The item scores range from 0 - not at all to 10- Extremely. Scores on all items are summed to attain the scale score, so individuals can score between 0-190. Higher scores indicates more severe withdrawal symptoms and greater negative impact. Change score was calculating by subtracting Day 1 CWS scores from Day 5 CWS scores. A positive change score reflects an increase in withdrawal symptoms, while a negative change score reflects a decrease in withdrawal symptoms.</description>
        <time_frame>Day 1 and Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Progesterone: Progesterone capsule</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Placebo: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cannabis Withdrawal Scale Score.</title>
          <description>Participants took progesterone or placebo for 5 days. The Cannabis Withdrawal Scale was administered each day. The 19-item scale is used to measure cannabis withdrawal symptoms and negative impact on daily life. The item scores range from 0 - not at all to 10- Extremely. Scores on all items are summed to attain the scale score, so individuals can score between 0-190. Higher scores indicates more severe withdrawal symptoms and greater negative impact. Change score was calculating by subtracting Day 1 CWS scores from Day 5 CWS scores. A positive change score reflects an increase in withdrawal symptoms, while a negative change score reflects a decrease in withdrawal symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.08" spread="4.15"/>
                    <measurement group_id="O2" value="20.41" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Progesterone</title>
          <description>Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Progesterone: Progesterone capsule</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
Placebo: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sherman</name_or_title>
      <organization>MUSC</organization>
      <phone>843-792-8174</phone>
      <email>shermanb@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

